Simplify Logo

Full-Time

Director – Commercial Packaging

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Hardware
Biotechnology

Compensation Overview

$216k - $239kAnnually

+ Equity Component

Senior, Expert

San Carlos, CA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • B.S. / B.A. degree in supply chain, business, life sciences, or other related discipline. Advanced Degree (preferred).
  • Minimum of 12 years’ experience in pharmaceutical packaging design & packaging operations supporting global markets with a minimum of 6-8 years of successful people management experience.
  • A solid understanding of packaging materials and manufacturing processes and experience in global packaging standards for drug products is required.
  • Ability to strategically plan, organize and manage multiple projects simultaneously.
  • Strong experience with Serialization.
  • Strong experience with Anticounterfeit Technologies.
  • Strong experience working with CMOs.
  • Strong experience with new product launches.
  • Strong knowledge of GMPs.
  • Experience with prefilled syringes strongly preferred.
  • Strong experience leading Cross-Functional teams.
  • Strong experience managing and building teams.
  • Excellent problem solving, communication and organizational skills.
  • Demonstrated expertise in critical thinking, influence, negotiation, problem solving, strategic thinking, and leadership in a matrix environment.
  • Excellent analytical skills.
  • Fluent in English.
Responsibilities
  • Develop global strategy for commercial assembly, labelling, secondary packaging, and serialization.
  • Provide technical leadership and management of teams that ensure timely product launch and ongoing supply for both domestic and international markets.
  • Lead selection, contracting and qualification of packaging sites.
  • Select vendors for package and artwork design.
  • Lead packaging design and artwork creation and approval process.
  • Define strategy, select, lead implementation, and manage the operation of serialization system/program.
  • Develop and implement product security and anticounterfeit strategy.
  • Manage the performance of all vendors including packaging sites, design vendors, component suppliers and serialization vendors.
  • Develop and manage plans to launch finished goods in new markets in alignment with regulatory approvals.
  • Develop and implement strategies for make to stock and make to order.
  • Proactively identify potential supply risks and initiate actions to mitigate.
  • Collaborate with commercial to develop and execute distribution strategies.
  • Design and implement robust and compliant track and trace procedures.
  • Collaborate with QA and Commercial to develop recall SOPs.
  • Build and maintain relationships with key stakeholders both internally and externally.
  • Lead recalls as needed.
  • Build and manage a team, providing mentorship, leadership, and growth.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to protect vulnerable populations from serious bacterial infections.

Company Stage

IPO

Total Funding

$2.3B

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

24%

1 year growth

53%

2 year growth

114%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.